RxDoctor Payments Data

Naveen Pesala, MD

Internal Medicine · New York, NYNPI 1346440823

Payments from drug & device makers

$79,640in general payments, 2019–2025

Across 285 payments — averaging $279.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$76K
  • Novo Nordisk$1K
  • Merck$532
  • AstraZeneca$426
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$403
  • Viiv Healthcare Company$362
  • plus $995 from 6 others

What the payments were for

  • Speaking & faculty fees$64,14881%
  • Travel & lodging$9,48812%
  • Food & beverage$5,9928%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$79,640 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$18,446
Medicare patients
14
Services billed
175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide14$19,662
JardianceEmpagliflozin21$17,508
FarxigaDapagliflozin Propanediol25$16,041
MounjaroTirzepatide11$11,006
JanuviaSitagliptin Phosphate17$9,129
XareltoRivaroxaban14$8,954
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,775
Rosuvastatin Calcium65$868
Valsartan25$560
Levothyroxine Sodium31$497
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril15$395
Ipratropium Bromide19$386
Colchicine14$372
Amlodipine Besylate84$349
Atorvastatin Calcium62$348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$1,011$19,66214 claims
AstraZenecaFarxiga$426$16,04125 claims
Lilly USA, LLCMounjaro$300$11,00611 claims
MerckJanuvia$532$9,12917 claims
Johnson & JohnsonXarelto$22$8,95414 claims
GSKTrelegy Ellipta$359$8,77514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →